STOCK TITAN

Becton, Dickinson and Company - BDX STOCK NEWS

Welcome to our dedicated page for Becton, Dickinson and Company news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Company stock.

Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.

BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.

Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.

In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.

BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.

Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.

With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.

Rhea-AI Summary

BD (NYSE: BDX) and Quest Diagnostics (NYSE: DGX) have announced a global collaboration agreement to develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx) for cancer and other diseases. This partnership aims to provide the pharmaceutical industry with an end-to-end solution for CDx development, ranging from exploratory panel development to FDA-approved diagnostic kit distribution.

The collaboration leverages BD's expertise in flow cytometry and Quest's proficiency in biomarker and assay development. Flow cytometry, an established laboratory technology, can rapidly analyze individual cells, potentially improving patient management and clinical outcomes. This initiative is expected to advance personalized medicine and potentially reduce healthcare costs by enabling more precise treatment selection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary

BD (Becton, Dickinson and Company), a leading global medical technology company, has announced a quarterly dividend declaration by its Board of Directors. The dividend, set at $0.95 per common share, will be payable on September 30, 2024 to shareholders of record as of September 9, 2024. This dividend announcement indicates an annual dividend rate of $3.80 per share. The declaration demonstrates BD's commitment to providing regular returns to its shareholders, potentially reflecting the company's financial stability and confidence in its future performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
dividends
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) announced a reduced availability of its BD BACTEC™ blood culture vials due to supplier issues. Addressing the supply shortfall, BD is implementing measures such as providing manufacturing expertise to the supplier, utilizing air shipments, adjusting production schedules, and collaborating with the FDA. To bridge the gap, BD is also engaging a former supplier to restart production of glass vials. Despite these challenges, BD assures it can meet most global demand and advises customers to prioritize vial usage based on clinical needs. The company expects no material financial impact from this issue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) announced it surpassed its FY 2023 Scope 1 and 2 greenhouse gas (GHG) emissions reduction targets by 5 percentage points. The company reported an 18% reduction in these emissions from a FY 2019 baseline, exceeding its target of 13%.

BD also gained approval for its near- and long-term emissions reduction plans from the Science Based Target initiative (SBTi), aligning its efforts with global climate goals. Additionally, the company has doubled the number of sites using Green Electric Power and on-site renewables since FY 2019. BD aims to achieve net zero GHG emissions across its value chain by FY 2050.

BD's sustainability initiatives and progress, including a commitment to reduce Scope 1 and 2 GHG emissions by 50% by 2030, are highlighted in their Fiscal Year 2023 Corporate Sustainability Report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) will announce its financial results for the third quarter of fiscal year 2024 on August 1, 2024. The report will be released at 6:30 a.m. Eastern Time (ET) and will be available on the company's investor relations website. The announcement will include summary financial information for the quarter ending June 30, 2024. Following the release, BD management will host an audio webcast at 8 a.m. ET to discuss the results, operations, and strategy updates. A replay of the webcast will be accessible on the same website shortly after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has launched the BD Rhapsody™ ATAC-Seq Assay, a new single-cell research tool to study molecular mechanisms of diseases like cancer and infectious diseases. This tool helps scientists analyze the epigenome at a single-cell level, enhancing their understanding of DNA regulation and disease progression. The assay is part of BD's comprehensive multiomics solutions portfolio, which includes other single-cell assays and bioinformatics tools. These tools aim to advance precision medicine by uncovering insights into rare cells implicated in various diseases. The BD Rhapsody™ Single-Cell Analysis System supports this new assay, available globally for purchase through BD representatives or their ecommerce portal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology leader, announced the dates for its upcoming earnings webcasts for the third and fourth quarters of fiscal year 2024. The third-quarter webcast is scheduled for Thursday, August 1, 2024, at 8:00 a.m. ET. The fourth-quarter webcast will take place on Thursday, November 7, 2024, at 8:00 a.m. ET. BD will release detailed announcements before each webcast to confirm the date and time of the earnings releases and webcasts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
-
Rhea-AI Summary

Edwards Lifesciences announced the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in cash. The transaction will enhance Edwards' financial flexibility and enable strategic investments in structural heart disease technologies. The deal is expected to close by the end of 2024, pending regulatory approvals. Edwards aims to focus on advancing innovations in aortic, mitral, tricuspid, and pulmonic treatments. The sale is anticipated to have an immaterial impact on adjusted EPS in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has announced an agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition aims to expand BD's portfolio of smart connected care solutions and enhance its position in advanced monitoring technologies.

Critical Care, a global leader in advanced patient monitoring, generated over $900 million in revenue in 2023 and employs approximately 4,500 people. The acquisition is expected to be immediately accretive to BD's revenue growth, adjusted gross and operating margins, and adjusted earnings per share.

Critical Care will operate as a separate business unit within BD's Medical segment and will continue to be based in Irvine, California, under the leadership of Katie Szyman. The transaction is expected to close by the end of the calendar year, subject to regulatory reviews and closing conditions.

BD plans to fund the acquisition with a combination of $1 billion in cash and $3.2 billion in new debt. The company expects to achieve additional margin expansion and value through cost synergies and efficiencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
Rhea-AI Summary

On May 15, 2024, BD (Becton, Dickinson and Company) announced FDA approval for the use of self-collected vaginal specimens for HPV testing when cervical specimens cannot be obtained. This approval allows women to collect samples in various healthcare settings, including non-traditional locales like retail pharmacies and mobile clinics. The BD Onclarity™ HPV Assay, which doesn't require a traditional Pap smear, enhances access to cervical cancer screening, particularly for underserved populations. Around 25% of U.S. women do not receive regular cervical cancer screenings, with higher rates of cervical cancer among Black, Hispanic, and American Indian women. This initiative aims to increase screening acceptance and participation, offering a significant advancement in cervical cancer prevention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none

FAQ

What does Becton, Dickinson and Company (BD) specialize in?

BD specializes in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products.

What are BD's main business segments?

BD’s main business segments include BD Medical, BD Life Sciences, and BD Interventional.

What recent projects has BD undertaken?

BD has collaborated on recycling used blood collection tubes in Denmark and launched new cell sorters for enhanced research in cell biology, cancer, and immunology.

How much of BD's revenue comes from international markets?

International revenue accounts for 43% of BD's total business.

What significant acquisition has BD announced recently?

BD announced the acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion.

How many employees does BD have?

BD has over 70,000 employees globally.

Where can I find more information about BD's financial performance?

Information about BD's financial performance can be found on their investor relations website at www.bd.com/investors.

What is the significance of the BD FACSDiscover™ S8 Cell Sorters?

The BD FACSDiscover™ S8 Cell Sorters enable real-time imaging and spectral flow cytometry, allowing researchers to gain new insights in various scientific fields.

Which regulatory body recently issued a safety communication regarding syringes?

The U.S. Food and Drug Administration (FDA) issued the safety communication.

What is BD's approach to sustainability?

BD is committed to sustainable innovation, including collaborations to recycle medical plastics and initiatives to minimize its environmental footprint.

Becton, Dickinson and Company

NYSE:BDX

BDX Rankings

BDX Stock Data

68.69B
289.01M
0.31%
88.08%
0.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
FRANKLIN LAKES